These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8424846)

  • 21. Long-lasting inhibition of 5-HT uptake of platelets in subjects treated by duloxetine, a potential antidepressant.
    Kasahara T; Ishigooka J; Nagata E; Murasaki M; Miura S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Feb; 16(1):25-31. PubMed ID: 8640460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats.
    Gobert A; Rivet JM; Cistarelli L; Melon C; Millan MJ
    J Neurochem; 1997 Dec; 69(6):2616-9. PubMed ID: 9375697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.
    Katofiasc MA; Nissen J; Audia JE; Thor KB
    Life Sci; 2002 Aug; 71(11):1227-36. PubMed ID: 12106588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.
    Auclair AL; Martel JC; Assié MB; Bardin L; Heusler P; Cussac D; Marien M; Newman-Tancredi A; O'Connor JA; Depoortère R
    Neuropharmacology; 2013 Jul; 70():338-47. PubMed ID: 23499664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duloxetine pharmacology: profile of a dual monoamine modulator.
    Karpa KD; Cavanaugh JE; Lakoski JM
    CNS Drug Rev; 2002; 8(4):361-76. PubMed ID: 12481192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrophysiological effects of fluoxetine and duloxetine in the dorsal raphe nucleus and hippocampus.
    Smith JE; Lakoski JM
    Eur J Pharmacol; 1997 Mar; 323(1):69-73. PubMed ID: 9105878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate.
    Wong DT
    Expert Opin Investig Drugs; 1998 Oct; 7(10):1691-9. PubMed ID: 15991911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.
    Deecher DC; Beyer CE; Johnston G; Bray J; Shah S; Abou-Gharbia M; Andree TH
    J Pharmacol Exp Ther; 2006 Aug; 318(2):657-65. PubMed ID: 16675639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
    Iyengar S; Webster AA; Hemrick-Luecke SK; Xu JY; Simmons RM
    J Pharmacol Exp Ther; 2004 Nov; 311(2):576-84. PubMed ID: 15254142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
    Beyer CE; Boikess S; Luo B; Dawson LA
    J Psychopharmacol; 2002 Dec; 16(4):297-304. PubMed ID: 12503828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The extracts of Fructus Akebiae, a preparation containing 90% of the active ingredient hederagenin: serotonin, norepinephrine and dopamine reuptake inhibitor.
    Jin ZL; Gao N; Zhou D; Chi MG; Yang XM; Xu JP
    Pharmacol Biochem Behav; 2012 Jan; 100(3):431-9. PubMed ID: 22005599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.
    Béïque JC; Lavoie N; de Montigny C; Debonnel G
    Eur J Pharmacol; 1998 May; 349(1):129-32. PubMed ID: 9669506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
    Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
    J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiophene derivatives: a new series of potent norepinephrine and serotonin reuptake inhibitors.
    Zhang A; Zhou G; Rong SB; Johnson KM; Zhang M; Kozikowski AP
    Bioorg Med Chem Lett; 2002 Apr; 12(7):993-5. PubMed ID: 11909701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor.
    Hou J; Xing Y; Zuo D; Wu Y; Tian J; Meng Q; Yang M
    Physiol Behav; 2015 Jan; 138():141-9. PubMed ID: 25447484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
    Orjales A; Mosquera R; Toledo A; Pumar MC; García N; Cortizo L; Labeaga L; Innerárity A
    J Med Chem; 2003 Dec; 46(25):5512-32. PubMed ID: 14640559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons.
    Guiard BP; Chenu F; El Mansari M; Blier P
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):211-23. PubMed ID: 20149268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats.
    Zhang R; Li X; Shi Y; Shao Y; Sun K; Wang A; Sun F; Liu W; Wang D; Jin J; Li Y
    PLoS One; 2014; 9(3):e91775. PubMed ID: 24614602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor, on monoamine system in mice and rats.
    Xue R; He XH; Yuan L; Chen HX; Zhang LM; Yong Z; Yu G; Fan SY; Li YF; Zhong BH; Zhang YZ
    J Pharmacol Sci; 2016 Jan; 130(1):1-7. PubMed ID: 26318675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.
    Chalon SA; Granier LA; Vandenhende FR; Bieck PR; Bymaster FP; Joliat MJ; Hirth C; Potter WZ
    Neuropsychopharmacology; 2003 Sep; 28(9):1685-93. PubMed ID: 12784100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.